zs pharma acquisition

Britain's AstraZeneca said on Friday it had agreed to buy U.S biotech company ZS Pharma for $2.7 billion, pipping Swiss firm Actelion … medicines are used by millions of patients worldwide. For more AstraZeneca announced today the successful completion of the tender offer for all of the outstanding shares of ZS Pharma (NASDAQ: ZSPH) and the subsequent acquisition of ZS Pharma as previously announced in November.. -releases/2015/AstraZeneca-strengthens-Cardiovascular-and-Metabolic-disease ZS Pharma General Information Description. OBLIGATION TO UPDATE ANY FORWARD-LOOKING STATEMENTS AS A RESULT OF DEVELOPMENTS The board of ZS Pharma has unanimously approved the terms of the agreement. are focused on addressing unmet needs in the medical community. RELIANCE ON THESE STATEMENTS. FibroGen in collaboration with AstraZeneca and Astellas. please visit: www.astrazeneca.com, Media Enquiries diseases. -9 complements the Company’s increasing focus on CKD and CHF, including the The global development programme is being conducted by Metabolic Disease, ING – Infection, Neuroscience and Gastrointestinal, Ensure your smart devices are better secured and durable to set your organization up for success. In a long-term safety and efficacy study, ZS-9 lowered serum potassium, maintained normokalemia, and was well tolerated for about 52 weeks. taxes, the same as the tender offer price. options have been limited. through life changing medicines. Acquisition includes potential best-in-class hyperkalaemia treatment and is expected to benefit AstraZeneca’s return to growth strategy . As of the expiration of the tender offer, a total of approximately 21,948,939 under Delaware law) were cancelled and converted into the right to receive all of the outstanding shares of ZS Pharma (NASDAQ: ZSPH) and the subsequent medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience A submission for AstraZeneca COMPLETES ACQUISITION OF ZS PHARMA. ZS Pharma chief executive officer Robert Alexander said: "This agreement will allow us to maximise the potential of ZS-9, drawing on AstraZeneca’s long-standing expertise in developing and commercialising medicines for cardiovascular and metabolic diseases. AstraZeneca is a global, innovation-driven biopharmaceutical business that "We look forward to joining AstraZeneca and to working together to bring this important treatment for hyperkalaemia to the global market, helping to meet an important unmet medical need for patients.". ZS Pharma develops and commercialises highly selective, non-absorbed drugs to treat renal, cardiovascular, liver and metabolic disorders. ZS Pharma, founded in 2008, is a publicly traded biopharmaceutical company ion-trap technology to develop new treatments of kidney and liver diseases that Actelion revealed in September it had initiated talks with ZS Pharma that could have led to a bid. for patients with anaemia associated with CKD, as well as its leading diabetes stages of their disease, with the goal of reducing morbidity and mortality ASTRAZENECA AND ZS PHARMA DISCLAIM ANY INTENT OR The potassium selectivity of ZS-9 allows high in-vitro binding capacity for potassium ions even if there are competing ions. Shared Services Coordinator in San Mateo, CA. One of the innovative medicines currently in CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS. AstraZeneca COMPLETES ACQUISITION OF ZS PHARMA AstraZeneca announced today the successful completion of the tender offer for all of the outstanding shares of ZS Pharma … THESE STATEMENTS ARE GENERALLY IDENTIFIED © Copyright 2021 The Canadian Business Journal. The transaction strengthens AstraZeneca’s cardiovascular and metabolic disease (CVMD) portfolio with the addition of the potassium-binding compound ZS-9 (sodium … The transaction strengthens … with a Prescription Drug User Fee Act goal date of 26 May 2016. Canada's Leading Online Business Magazine. The acquisition is structured as an all-cash tender offer for all outstanding shares of ZS Pharma common stock at a price of $90 per share, followed by … The acquisition is structured as an all-cash tender offer for all outstanding shares of ZS Pharma common stock at a price of $90 per share, followed by a merger in which each remaining untendered share of ZS Pharma common stock would be converted into the same $90 … AstraZeneca has entered into a definitive agreement to acquire ZS Pharma, a biopharmaceutical company based in San Mateo (California, USA). $90.00 per share in cash, without interest and less any required withholding With AstraZeneca’s $2.7bn purchase of ZS Pharma and its hyperkalaemia project ZS-9 turning increasingly sour, its rival Relypsa became a prominent acquisition target. owned subsidiary of AstraZeneca. AstraZeneca announced today the successful completion of the tender offer for all of the outstanding shares of ZS Pharma (NASDAQ: ZSPH) and the subsequent acquisition of ZS Pharma as previously announced in November.. AstraZeneca strengthens cardiovascular and metabolic disease portfolio with acquisition of ZS Pharma Details AstraZeneca 06 November 2015 AstraZeneca announced today that it has entered into a definitive agreement to acquire ZS Pharma (NASDAQ: ZSPH), a biopharmaceutical company based in San Mateo, California. AstraZeneca COMPLETES ACQUISITION OF ZS PHARMA . The purpose of the Merger is to acquire all capital stock of ZS Pharma not purchased pursuant to the Offer or otherwise and to cause ZS Pharma to become a wholly owned subsidiary of Parent. Lindsey Trickett Oncology, ING +1 240 543 7970 AstraZeneca announced today the successful completion of the tender offer for SOME OF THE STATEMENTS CONTAINED IN THIS ANNOUNCEMENT ARE FORWARD LOOKING ZS Pharma develops and commercialises highly selective, non-absorbed drugs to treat renal, cardiovascular, liver and metabolic disorders. Pharma’s outstanding shares. ZS-9 is under regulatory review by the US Food and Drug Administration (CHF). The acquisition is structured as an all-cash tender offer for all outstanding shares of ZS common stock, followed by a merger in which each remaining untendered share of ZS Pharma common stock would be converted into the same $90 cash per share consideration as in the tender offer. acquisition of ZS Pharma as previously announced in AstraZeneca completes acquisition of ZS Pharma: United Kingdom Friday, December 18, 2015, 15:00 Hrs [IST] AstraZeneca announced that the company successfully completed the tender offer for all of the outstanding shares of ZS Pharma and the subsequent acquisition of ZS Pharma as previously announced in November. ThreeD Capital Inc. The acquisition is structured as an all-cash tender offer for all outstanding shares of ZS Pharma common stock at a price of $90 per share, followed by a merger in which each remaining untendered share of ZS Pharma common stock would be converted into the same $90 cash per share consideration as in the tender offer. dedicated to challenging the status quo in disease states where therapeutic Nick Stone CVMD +44 7717 618834 accepted for payment in the tender offer (excluding shares held as treasury Public benefit: could the PBC model help pharma balance profits and patients? We use cookies to ensure that we give you the best experience on our website. ZS Pharma represents a strong fit with AstraZeneca’s pipeline and portfolio in Cardiovascular & Metabolic Disease, one of the company’s three main therapy areas. PROVE INACCURATE OR UNKNOWN RISKS OR UNCERTAINTIES MATERIALIZE, ACTUAL RESULTS BY WORDS OR PHRASES SUCH AS “BELIEVE,” “ANTICIPATE,” “EXPECT,” “INTEND,” “PLAN,” DECEMBER 31, 2014 AND SUBSEQUENT QUARTERLY REPORTS ON FORM 10-Q, AS WELL AS THE ZS is a professional services firm that works side by side with companies to help develop and deliver products that drive customer value and company results. ", 8 November 2015 (Last Updated November 8th, 2015 18:30). Vanessa Rhodes UK/Global +44 20 7604 8037 (excluding shares tendered pursuant to notices of guaranteed delivery for which IF UNDERLYING ASSUMPTIONS AstraZeneca’s strategy focuses on reducing morbidity, mortality and organ damage by addressing multiple risk factors across cardiovascular disease, diabetes and chronic kidney disease. American Rescue Plan is a watershed moment for US recovery – leading macroeconomic influencers, Incyte’s Covid-19 associated ARDS study fails to meet primary endpoint, Medolife Rx reports positive data from Covid-19 drug candidate study, Exscientia raises $100m Series C funding to develop fully autonomous drug design, Takeda exercises option to acquire Maverick Therapeutics for $525m, Amgen signs agreement to acquire Five Prime Therapeutics for $1.9bn, EMA review concludes AstraZeneca Covid-19 vaccine is “safe and effective”, Pfizer/BioNTech’s Comirnaty forecast to reach record-breaking peak sales within two years of launch, Moving towards COVID-safe workspaces with the Nymi Band™️, Federal Trade Commission forms multilateral working group on pharma mergers, Philippines approves Sputnik V Covid-19 vaccine for emergency use. NEGATIVE OF SUCH TERMS OR OTHER SIMILAR EXPRESSIONS. shares of ZS Pharma common stock were validly tendered and not withdrawn DISCUSSED IN THE FORWARD-LOOKING STATEMENTS, AND YOU SHOULD NOT PLACE UNDUE About AstraZeneca in Cardiovascular & Metabolic Disease (CVMD). Michele Meixell US +1 302 885 2677 (CVMD) portfolio with the addition of the potassium-binding compound ZS-9 ZS Pharma uses its proprietary ion-trap technology to develop novel treatments for hyperkalaemia (high … portfolio, a comorbidity often associated with CKD and CHF patients. hyperkalaemia, a condition associated with increased mortality in patients with The acquisition represents a gamble by AstraZeneca on ZS-9 winning a green light from regulators; it said potential peak global sales for the drug were estimated to exceed $1bn. focuses on the discovery, development and commercialisation of prescription Dial / Toll-Free +1 866 381 7277. Thomas Kudsk Larsen Oncology +44 7818 524185 investigational medicine roxadustat, which is currently in Phase III development The US firm uses its ion-trap technology to develop new treatments for hyperkalaemia, a serious condition of high potassium levels in the bloodstream, typically associated with chronic kidney disease (CKD) and chronic heart failure (CHF). ZS-9 complements AstraZeneca’s increasing focus on CKD and CHF, including the investigational medicine roxadustat, which is currently in Phase III development for patients with anaemia associated with CKD, as well as its leading diabetes portfolio. ZS Pharma uses its proprietary ion-trap technology to develop novel treatments for hyperkalaemia (high potassium levels), a serious condition of elevated potassium in the bloodstream, typically associated with chronic kidney disease (CKD) and … As with any acquisition, it is also currently going through the growing pains of integrating some areas with the parent organization, and keeping other parts intact. We look forward to welcoming the ZS Pharma team to AstraZeneca.". The company is focused on the development and commercialization of highly selective, non-systemically absorbed therapeutics to treat renal, cardiovascular, liver and metabolic diseases. Craig Marks Finance +44 7881 615764 AstraZeneca has completed its previously announced tender offer for all of the outstanding shares of ZS Pharma, a biopharmaceutical company based in San Mateo, California, for $2.7 billion, and the subsequent acquisition of the company. Operator of a biopharmaceutical company. The company has been focused on using its proprietary After multiple rejections, the U.S. Food and Drug Administration (FDA) finally gave its approval for the treatment that was the primary focus of the 2015 $2.7 billion acquisition of ZS Pharma. connection with the merger, each outstanding share of ZS Pharma that was not BASED ON CURRENT EXPECTATIONS, ASSUMPTIONS, ESTIMATES AND PROJECTIONS, AND Image: AstraZeneca headquarters in London, UK. Clearly, there was a bidding war for ZS Pharma. pursuant to the tender offer, AstraZeneca completed its acquisition of ZS Pharma withdrawn pursuant to the tender offer were accepted for payment today. European Marketing Application Authorisation is also progressing as planned. AND THE TIMING OF EVENTS MAY DIFFER MATERIALLY FROM THE RESULTS AND/OR TIMING The Offer, as the first step in the acquisition of ZS Pharma, is intended to facilitate the acquisition of all of the Shares. The tender offer expired at 00:00 EST on 16 December 2015 and was not extended. Under the deal, AstraZeneca will pay $90 a share for ZS Pharma, which employs about 200 people across three sites in California, Texas and Colorado. Globalstar Announces Next Generation Technology Agreement With Yippy, Inc. Samsung Built to Last in Tough Environments, Delaying Your CPP Benefits is a Smart Move, Investments in Education and Training Critical to Long-Term Recovery, Disability – Inclusive Hiring Crucial For Business Growth and Success Post-Pandemic, ASTRAZENECA COMPLETES ACQUISITION OF ZS PHARMA, Vote in favor of revocation of the union certification following an application by an employee of Laurentian Bank, Rapid Dose Therapeutics Closes Purchase and Amalgamation of Consolidated Craft Brands. (sodium zirconium cyclosilicate), a potential best-in-class treatment for In chronic kidney disease (CKD), diabetes mellitus (DM), and chronic heart failure We connect the dots across organizations leveraging analytics, technology and strategy to deliver solutions to the most difficult business challenges. Sorry, your blog cannot share posts by email. Source: 4-traders ZS Pharma: ZS Pharma : AstraZeneca completes acquisition of ZS Pharma (4-traders.com) AstraZeneca announced today the successful completion of the tender offer for all of the outstanding shares of ZS Pharma (NASDAQ: ZSPH) and the subsequent acquisition of ZS Pharma as previously announced in November. AstraZeneca has completed its $2.7-billion acquisition of ZS Pharma, bolstering its cardiovascular and metabolic disease portfolio. "This acquisition complements our strategic focus on Cardiovascular and Metabolic Disease by adding a potential best-in-class treatment to our portfolio of innovative medicines. ZS-9 complements the company’s … -portfolio-with-acquisition-of-ZS-Pharma-06112015.html). AstraZeneca is expanding its cardiovascular and metabolic disease portfolio with the acquisition of US-based biopharmaceutical firm ZS Pharma for about $2.7bn. leadership and returning to growth. addressing the multiple risk factors facing CVMD and CKD patients at different AND OTHER RISKS AND UNCERTAINTIES DISCUSSED IN ZS PHARMA’S PUBLIC FILINGS WITH Phase III development is roxadustat as a potential therapy for anaemia information, please visit: www.zspharma.com. UK Key: RIA – Respiratory, Inflammation and Autoimmunity, CVMD – Cardiovascular and ZS Pharma’s shares ceased to be listed on NASDAQ, and ZS Pharma became a wholly Post was not sent - check your email addresses!